Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02508194 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1,900
- Enrollment target
NCT02508194: Clinical Trial Phase 2 study, sponsored by MedImmune.
NCT02508194 is a Phase 2 study that was terminated before completion, run by MedImmune. The registered enrollment target is 1,900 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1329% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02508194, a Phase 2 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1,900 participants
- Enrollment target
Study Summary
This study will be the first assessment of the efficacy of MEDI7510 for the prevention of respiratory syncytial virus (RSV) disease. It will also provide estimates of vaccine efficacy and of endpoint incidence in the placebo arm. It will also assess the safety and immunogenicity of concurrent dosing of MEDI7510 and IIV to expand on the observations made in the Phase 1b study of MEDI7510. It will also expand the safety database of participants dosed with MEDI7510. The study will also assess the immune response to MEDI7510 in Season 1 and Season 2.
Primary Outcome
ARA-RI was defined as an event in which a participant met specified clinical criteria and the event was laboratory-confirmed to be RSV-related. The specified clinical criteria included a minimum of 1 symptom from any 2 of the 3 symptom columns: one symptom from upper respiratory symptom column and one symptom from lower respiratory symptom column; one symptom from upper respiratory symptom column and one symptom from systemic symptom column; or one symptom from lower respiratory column and one f
Interventions
- OTHER Placebo
- BIOLOGICAL MEDI7510
- BIOLOGICAL IIV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,900 participants |
| Start Date | 2015-09-29 |
| Est. Completion | 2016-11-07 |
| Phase | Phase 2 |
Why NCT02508194 stopped before completion
NCT02508194 is an interventional study that assigns participants to a tested intervention. Its 1,900 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1329% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02508194 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02508194 about?
NCT02508194 is a clinical study titled "A Study to Evaluate the Efficacy of MEDI7510 in Older Adults". This study will be the first assessment of the efficacy of MEDI7510 for the prevention of respiratory syncytial virus (RSV) disease. It will also provide estimates of vaccine efficacy and of endpoint incidence in the placebo arm. It will also assess the safety and immunogenicity of concurrent dosing...
What is the current status of trial NCT02508194?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1,900 participants. The study started on 2015-09-29. Estimated completion is 2016-11-07.
What interventions are being tested in trial NCT02508194?
The interventions under investigation include: Placebo (OTHER), MEDI7510 (BIOLOGICAL), IIV (BIOLOGICAL).
Who is sponsoring clinical trial NCT02508194?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02508194's enrollment target sits among peer trials
1,900 10th of 2000 higher than 1,991 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- NCT06929806 · 1,900 participants · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
- NCT07228234 · 1,900 participants · NA
Evaluating Mammography Communication Approaches
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI